Brensocatib
Brensocatib is an oral, reversible DPP1 inhibitor that reduces the activity of neutrophil serine proteases, validated in bronchiectasis. Insmed has also evaluated it in other neutrophilic diseases, including chronic rhinosinusitis without nasal polyps (the BiRCh study).
Also known as: INS1007, AZD7986
Brensocatib forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Brensocatib
What is Brensocatib?
Brensocatib is an oral, reversible DPP1 inhibitor that reduces the activity of neutrophil serine proteases, validated in bronchiectasis. Insmed has also evaluated it in other neutrophilic diseases, including chronic rhinosinusitis without nasal polyps (the BiRCh study). It is a oral reversible dpp1 inhibitor developed by Insmed.
What does Brensocatib target?
Brensocatib acts on Dipeptidyl peptidase-1 (DPP1 / cathepsin C).
How well do AI models predict Brensocatib trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.